Advaxis (NASDAQ:ADXS) Stock Price Passes Above 200 Day Moving Average of $0.58

Share on StockTwits

Advaxis, Inc. (NASDAQ:ADXS)’s stock price passed above its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $0.58 and traded as high as $1.00. Advaxis shares last traded at $0.98, with a volume of 4,657,034 shares trading hands.

Separately, Zacks Investment Research downgraded shares of Advaxis from a “buy” rating to a “hold” rating in a research report on Wednesday, October 30th.

The firm’s 50 day simple moving average is $1.03 and its two-hundred day simple moving average is $0.58. The stock has a market capitalization of $64.44 million, a P/E ratio of -23.61 and a beta of 4.13.

Advaxis (NASDAQ:ADXS) last issued its earnings results on Friday, December 20th. The biotechnology company reported ($0.15) EPS for the quarter. Advaxis had a negative net margin of 79.31% and a negative return on equity of 40.98%.

A number of large investors have recently made changes to their positions in the business. Renaissance Technologies LLC increased its holdings in shares of Advaxis by 90.9% during the fourth quarter. Renaissance Technologies LLC now owns 3,780,083 shares of the biotechnology company’s stock valued at $3,242,000 after acquiring an additional 1,800,297 shares in the last quarter. Sabby Management LLC lifted its holdings in shares of Advaxis by 3,547.9% in the 3rd quarter. Sabby Management LLC now owns 1,521,982 shares of the biotechnology company’s stock worth $403,000 after purchasing an additional 1,480,260 shares in the last quarter. Geode Capital Management LLC lifted its holdings in shares of Advaxis by 823.4% in the 4th quarter. Geode Capital Management LLC now owns 452,146 shares of the biotechnology company’s stock worth $387,000 after purchasing an additional 403,183 shares in the last quarter. Vanguard Group Inc. lifted its holdings in shares of Advaxis by 71.1% in the 2nd quarter. Vanguard Group Inc. now owns 230,106 shares of the biotechnology company’s stock worth $481,000 after purchasing an additional 95,607 shares in the last quarter. Finally, Raymond James Financial Services Advisors Inc. grew its position in Advaxis by 206.3% in the 4th quarter. Raymond James Financial Services Advisors Inc. now owns 50,000 shares of the biotechnology company’s stock valued at $43,000 after purchasing an additional 33,675 shares during the period. Institutional investors and hedge funds own 8.09% of the company’s stock.

About Advaxis (NASDAQ:ADXS)

Advaxis, Inc, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of Listeria monocytogenes (Lm) technology based antigen delivery product in the United States. It is developing therapies for HPV-related cancers using axalimogene filolisbac (AXAL) for the treatment of head and neck cancer.

See Also: Monthly Dividend Stocks Can Provide Solid Income

Receive News & Ratings for Advaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis and related companies with MarketBeat.com's FREE daily email newsletter.